Skip to main content
SpringerLink
Log in

Melanoma ± autoimmune disease: tolerability of checkpoint inhibitors

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Van der Kooij MK, et al. Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease. A Cohort Study. Annals of Internal Medicine : 16 Feb 2021. Available from: URL: https://doi.org/10.7326/M20-3419

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Melanoma ± autoimmune disease: tolerability of checkpoint inhibitors. Reactions Weekly 1845, 9 (2021). https://doi.org/10.1007/s40278-021-91892-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-021-91892-x

Search

Navigation